Core Viewpoint - The European Commission has approved a new indication for Sugrilimab, allowing its use as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK/ROS1 genomic alterations, and have not experienced disease progression after platinum-based chemoradiotherapy [1] Company Summary - 基石药业's CEO, Dr. Yang Jianxin, highlighted that this new indication approval comes just one year after the first approval for Sugrilimab in the first-line treatment of metastatic squamous and non-squamous NSCLC, marking comprehensive coverage from stage III to IV NSCLC in Europe [1] - The company aims to enhance the accessibility of Sugrilimab globally, reaffirming its long-term commitment to patients [1] Industry Summary - The approval of Sugrilimab as the second PD-(L)1 antibody for stage III NSCLC in Europe addresses a critical treatment need in this disease area [1] - The efficient execution of the clinical development and registration team at 基石药业 has ensured a swift and smooth approval process under the European Medicines Agency (EMA) review pathway [1]
基石药业-B(02616.HK)：舒格利单抗获欧盟委员会批准用于治疗Ⅲ期非小细胞肺癌